Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Susan Ling, Felicia Ceban, Leanna M.W. Lui, et al.
CNS Drugs (2021) Vol. 36, Iss. 1, pp. 17-30
Closed Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

New and emerging approaches to treat psychiatric disorders
Katherine W. Scangos, Matthew W. State, Andrew H. Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 317-333
Closed Access | Times Cited: 72
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Stephanie Knatz Peck, Samantha Shao, Tessa Gruen, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1947-1953
Open Access | Times Cited: 70
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Sipan Haikazian, David Chen‐Li, Danica E. Johnson, et al.
Psychiatry Research (2023) Vol. 329, pp. 115531-115531
Closed Access | Times Cited: 46
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 24
Emerging paradigms for target discovery of traditional medicines: A genome-wide pan-GPCR perspective
Zenghao Bi, Huan Li, Yuting Liang, et al.
The Innovation (2025) Vol. 6, Iss. 3, pp. 100774-100774
Open Access | Times Cited: 2
Therapeutic use of psilocybin: Practical considerations for dosing and administration
Caroline A. MacCallum, Lindsay A. Lo, Carly A. Pistawka, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 49
Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents
Erika Plazas, Nicoletta Faraone
Biomedicines (2023) Vol. 11, Iss. 2, pp. 461-461
Open Access | Times Cited: 23
Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms
Kyna‐Anne Conn, Laura K Milton, Kaixin Huang, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 10, pp. 3291-3304
Open Access | Times Cited: 15
Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder
Chloe E. Page, C. Neill Epperson, Andrew M. Novick, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 12, pp. 3802-3813
Closed Access | Times Cited: 12
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e121-e132
Closed Access | Times Cited: 9
Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice
Youge Qu, Lijia Chang, Li Ma, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 222, pp. 173500-173500
Closed Access | Times Cited: 32
From helplessness to controllability: toward a neuroscience of resilience
Michael V. Baratta, Martin E. P. Seligman, Steven F. Maier
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 18
The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation
Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li, et al.
Genes (2024) Vol. 15, Iss. 2, pp. 183-183
Open Access | Times Cited: 6
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Noah Chisamore, Danica E. Johnson, Margery J.Q. Chen, et al.
Journal of Psychiatric Research (2024) Vol. 176, pp. 77-84
Closed Access | Times Cited: 6
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Terence H. W. Ching, Rachael Grazioplene, Calvin Bohner, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 15
The separation distress hypothesis of depression – an update and systematic review
Douglas F. Watt
Neuropsychoanalysis (2023) Vol. 25, Iss. 2, pp. 103-159
Open Access | Times Cited: 15
The Effects of Psilocybin on Lipopolysaccharide-Induced Inflammation in THP-1 Human Macrophages
Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li, et al.
Psychoactives (2024) Vol. 3, Iss. 1, pp. 48-64
Open Access | Times Cited: 5
Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials
Shuping Fang, Xin Yang, Wei Zhang
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles
Hans O. Kalkman
Biomedicines (2023) Vol. 11, Iss. 3, pp. 806-806
Open Access | Times Cited: 12
Prophylactic effects of arketamine, but not hallucinogenic psychedelic DOI nor non-hallucinogenic psychedelic analog lisuride, in lipopolysaccharide-treated mice and mice exposed to chronic restrain stress
Guilin Liu, Li Ma, Youge Qu, et al.
Pharmacology Biochemistry and Behavior (2023) Vol. 233, pp. 173659-173659
Closed Access | Times Cited: 12
Psilocybin for major depressive disorder: a systematic review of randomized controlled studies
Lijuan Li, Mo Yu, Zhan-Ming Shi, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats
Zitong Wang, Brett Robbins, R. L. Zhuang, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111243-111243
Open Access
Psychedelics as moral bioenhancers: Protocol for a scoping review of ethical arguments for and against
S L Streicher, Christopher Register, Xiu Lim, et al.
Wellcome Open Research (2025) Vol. 10, pp. 3-3
Open Access
Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights
I. Craig Henderson, Ronnie Elsaadany, Gabriel Chan, et al.
Current Pain and Headache Reports (2025) Vol. 29, Iss. 1
Closed Access
Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps
Eyal Kurzbaum, Tomáš Páleníček, Amiel Shrchaton, et al.
Journal of Fungi (2025) Vol. 11, Iss. 2, pp. 99-99
Open Access
Page 1 - Next Page

Scroll to top